drugset / Trial / NCT00483496

Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)

NCT00483496 ↗

Phase 2 Completed 16 enrolled Orfagen
RandomizedCrossoverSingle-blindSupportive care

Summary

Commercially available external photoprotectors (EP) do not provide adequate protection against ultraviolet A (UVA) and visible wavelengths. The proposed medicinal product V0096 CR (formula RV3131A-MV1166) is a broad spectrum EP (bsEP). The rationale for the use of V0096 CR (formula RV3131A-MV1166) in the proposed condition is based on its ability to broadly block the UVA radiations and visible light that are known to trigger solar urticaria (SU).

Timeline

Start
2007-09
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ti02 pigmentary Unknown 3 % Topical
Subject Titanium dioxide (Ti02) microfine Unknown 12.15 % Topical
Subject bisoctrizole Small molecule 10 % Topical

Indications